Metrics to compare | KZR | Peers Peers - average of corresponding metrics from companies closely matching KZR: | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipKZRPeersSector |
|---|---|---|---|---|
P/E Ratio | −1.0x | 0.0x | −0.5x | |
PEG Ratio | −0.03 | 0.00 | 0.00 | |
Price/Book | 0.8x | 0.0x | 2.6x | |
Price / LTM Sales | - | 0.0x | 3.0x | |
Upside (Analyst Target) | −18.8% | 0.0% | 58.6% | |
Fair Value Upside | Unlock | 0.0% | 10.2% | Unlock |
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company’s lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. As of May 11, 2026, Kezar Life Sciences, Inc. operates as a subsidiary of Aurinia Pharma U.S., Inc.